Urocit-K XR Shortage Update: What Patients Need to Know in 2026

If you've been struggling to fill your Urocit-K XR prescription and you're wondering whether there's a nationwide shortage, you deserve a straight answer. Here's the current status of potassium citrate extended-release availability in 2026 — and what it means for you as a patient.

Is Urocit-K XR Officially in Shortage in 2026?

As of 2026, potassium citrate extended release (the generic name for Urocit-K XR) is not listed on the FDA's official drug shortage database. This means it is not experiencing the kind of widespread, multi-manufacturer shortage seen with drugs like Adderall or certain antibiotics. However, that doesn't mean it's always in stock at your local pharmacy.

Drugs.com notes that stock shortages and other unknown variables can affect availability, particularly for specific strengths of the brand-name Urocit-K. What patients are experiencing is more accurately described as

spotty, localized stocking gaps rather than a formal national shortage.

What Is Causing the Availability Issues?

Several factors contribute to why patients sometimes have difficulty finding Urocit-K XR:

Specialty tablet manufacturing. Urocit-K XR uses a wax-matrix extended-release formulation that requires specialized manufacturing equipment and processes. This makes production more complex than standard tablets.

Stocking decisions at the pharmacy level. Pharmacies stock medications based on local demand. Less commonly prescribed strengths (5 mEq and 15 mEq) may not be kept in adequate supply at all locations.

Brand vs. generic supply chains. The brand-name Urocit-K (Mission Pharmacal) and multiple generic versions have separate supply chains. A shortage in brand supply doesn't necessarily affect generics, and vice versa.

Distribution timing. Even when the medication is available at the wholesale level, a pharmacy may be temporarily out between weekly shipments.

Has There Been a History of Urocit-K Shortages?

Urocit-K has a long history on the market — it was FDA-approved in 1985. While it has not been subject to the dramatic nationwide shortages seen with some high-demand medications, patients with kidney stone disease and renal tubular acidosis have periodically reported difficulty filling prescriptions, particularly for higher-strength tablets like the 15 mEq formulation. These gaps tend to be regional and temporary rather than nationwide.

How Serious Is It If You Miss Doses?

Missing a few days of Urocit-K XR is unlikely to cause an immediate kidney stone. However, the medication works by continuously keeping urinary citrate elevated and urinary pH in the optimal range (6.0–7.0). Extended gaps — more than a week or two — allow stone-forming conditions to return. Patients with a history of rapid stone formation should be especially diligent about maintaining their supply.

Steps to Take if You're Having Trouble Getting Urocit-K XR

Use medfinder: medfinder contacts pharmacies near you to check which ones have Urocit-K XR in stock, saving you hours of calling.

Ask for the generic version. Generic potassium citrate ER is FDA-approved and therapeutically equivalent. It is often more widely available than brand-name Urocit-K.

Ask your pharmacist about wholesaler availability. Your pharmacist can check real-time inventory at their distributor and may be able to receive a shipment within 1–2 business days.

Talk to your doctor about dose flexibility. Your prescriber may be able to prescribe an equivalent total daily dose using a different strength that's easier to find.

Ask about short-term alternatives. Review our guide to Urocit-K XR alternatives to discuss temporary options with your prescriber.

Stay Proactive About Your Refills

The most important thing kidney stone patients can do is stay proactive. Request refills at least 7–10 days before running out. If you're on a maintenance dose, consider a 90-day supply through mail-order pharmacy to reduce the risk of running out between fills. Staying well-hydrated and following a low-sodium diet can also help minimize stone risk during any supply gaps.